Shares of Akero Therapeutics AKRO skyrocketed 105.7% in a week after the company announced initial positive top line 96-week ...

Shares of Novo Nordisk NVO gained 8.5% on Friday after the company announced positive top-line data from an early to ...

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...

Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...

How far would you go to lose weight? After much international hype, weight management drug Wegovy has been offered at the GHA for a number of months. Speaking on Gibraltar Today, Dr Alfonso Antequera ...

Sales of Novo Nordisk’s semaglutide medicines, Ozempic and Rybelsus for type II diabetes and Wegovy for weight loss were also disappointing in the third quarter, with not much expectation of ...

Weight loss jabs such as Wegovy are “lifelong treatments” and most people who stop taking them will lose the effects, a scientist who developed the revolutionary drugs has said. Professor ...

Circle Chart (formerly known as Gaon Chart) has published its year-end charts for 2024! Because the yearly charts are based on accumulated weekly data since the beginning of January 2024 ...

That’s largely because the country is home to Novo Nordisk, the maker of Ozempic and Wegovy, the popular weight-loss drugs. The company is so important to the Danish economy — it has recently ...

"Ozempic is the only version among the weekly injectables — Ozempic, Wegovy, Zepbound and Mounjaro — that has the option to ‘hack’ the pen for a smaller dose," Dr. Alexandra Sowa ...